Latest Prostate Specific Antigen News
Shorter PSA double times are associated with worse disease-specific, metastasis-free, and overall survival, study finds.
Findings for men with intermediate- and high-risk prostate cancer.
IsoPSA can correctly rule out high-grade prostate cancer 93% of the time and thus has the potential to reduce the number of unnecessary prostate biopsies.
Investigators suggest PSA testing frequencies based on post-operative baseline PSA.
Men with Gleason score (GS) 4+3 prostate cancer have a 3-fold higher risk of distant metastasis at diagnosis than those with GS 3+4 PCa.
Findings from a large study of men in the United Kingdom do not support single PSA testing for population-based screening.
Among men who had PSA failure following radiation therapy for localized PCa, those with a long PSA doubling time had an increased risk of PCa mortality if they started androgen-deprivation therapy later.
PSA levels of 10 ng/mL or higher in men who have biochemically recurrent PCa after radical prostatectomy and a PSADT less than 12 months are at imminent risk for metastatic disease.
A detectable PSA nadir combined with shorter time to nadir after prostate cancer surgery is associated with a higher risk of biochemical recurrence.
Over 15 years of follow-up, considerable proportion of men undergo prostate-specific antigen testing
Men with PSA values of 2.5 ng/mL or less and Gleason 8 to 10 prostate tumors are at higher risk of death than other high-risk PCa patients.
The new test, IsoPSA, measures all PSA isoforms in serum and more accurately discriminates high-grade cancer from benign disease.
Spike in PSA level after starting abiraterone does not affect progression-free or overall survival, study finds.
Also increased risk of progression to metastatic disease compared with the general population.
The US Preventive Services Task Force now suggests decisions about PSA testing should be made on an individual basis for men aged 55 to 69.
Renal and Urology News Articles
- FDA Recalls Drugs Containing Active Ingredient Valsartan
- Correcting Metabolic Acidosis May Preserve Muscle Mass
- Infection Risk Lower in Dialysis Patients With High, Normal Vitamin D
- Urine Cytology May Not Improve Hematuria Evaluation for Bladder Cancer
- Aggressive Therapy Warranted for Gleason 10 Prostate Cancer
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)